This study identified that CD8 + CXCR5 + T cells were a potent subset of CD8 + T cells that were highly enriched in pancreatic cancer patients and could respond to anti-PD-1/anti-TIM-3 blockade by further regulating function [128]. This evidence concerns the gene HAVCR2 and pancreatic neoplasm.